FI3789389T3 - (S)-N-[5-[l-(3-etoksi-4-metoksifenyyli)-2-(metyylisulfonyyli)etyyli]-4,6-diokso-5,6-dihydro-4H-tieno[3,4-c]pyrrol-1-yyli]asetamidin kidemuoto - Google Patents

(S)-N-[5-[l-(3-etoksi-4-metoksifenyyli)-2-(metyylisulfonyyli)etyyli]-4,6-diokso-5,6-dihydro-4H-tieno[3,4-c]pyrrol-1-yyli]asetamidin kidemuoto

Info

Publication number
FI3789389T3
FI3789389T3 FIEP19797143.5T FI19797143T FI3789389T3 FI 3789389 T3 FI3789389 T3 FI 3789389T3 FI 19797143 T FI19797143 T FI 19797143T FI 3789389 T3 FI3789389 T3 FI 3789389T3
Authority
FI
Finland
Prior art keywords
thieno
dioxo
methylsulfonyl
methoxyphenyl
dihydro
Prior art date
Application number
FIEP19797143.5T
Other languages
English (en)
Finnish (fi)
Inventor
Donglei Zhang
Liyu Wang
Yukun Chang
Original Assignee
Tianjin Hemay Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Hemay Pharmaceutical Co Ltd filed Critical Tianjin Hemay Pharmaceutical Co Ltd
Application granted granted Critical
Publication of FI3789389T3 publication Critical patent/FI3789389T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
FIEP19797143.5T 2018-05-02 2019-04-30 (S)-N-[5-[l-(3-etoksi-4-metoksifenyyli)-2-(metyylisulfonyyli)etyyli]-4,6-diokso-5,6-dihydro-4H-tieno[3,4-c]pyrrol-1-yyli]asetamidin kidemuoto FI3789389T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810407741 2018-05-02
PCT/CN2019/085327 WO2019210864A1 (zh) 2018-05-02 2019-04-30 噻吩衍生物的晶型

Publications (1)

Publication Number Publication Date
FI3789389T3 true FI3789389T3 (fi) 2025-11-19

Family

ID=68386284

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP19797143.5T FI3789389T3 (fi) 2018-05-02 2019-04-30 (S)-N-[5-[l-(3-etoksi-4-metoksifenyyli)-2-(metyylisulfonyyli)etyyli]-4,6-diokso-5,6-dihydro-4H-tieno[3,4-c]pyrrol-1-yyli]asetamidin kidemuoto

Country Status (14)

Country Link
US (4) US11396518B2 (enExample)
EP (5) EP3800190A4 (enExample)
JP (5) JP7477459B2 (enExample)
KR (4) KR102686835B1 (enExample)
CN (7) CN116836178A (enExample)
AU (4) AU2019262284A1 (enExample)
BR (4) BR112020022190A2 (enExample)
CA (4) CA3099072A1 (enExample)
DK (1) DK3789389T3 (enExample)
ES (1) ES3047059T3 (enExample)
FI (1) FI3789389T3 (enExample)
PL (1) PL3789389T3 (enExample)
PT (1) PT3789389T (enExample)
WO (4) WO2019210865A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3800190A4 (en) * 2018-05-02 2022-01-26 Tianjin Hemay Pharmaceutical Co., Ltd. SOLID FORM OF THIOPHENE DERIVATIVE
WO2025103428A1 (zh) * 2023-11-14 2025-05-22 赣州和美药业股份有限公司 中重度斑块型银屑病的治疗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
WO2003091260A1 (en) * 2002-04-23 2003-11-06 Dr. Reddy's Laboratories Limited Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof
CN101186612B (zh) 2006-11-15 2012-10-03 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
CN108059635B (zh) * 2009-05-14 2021-10-01 天津合美医药科技有限公司 噻吩衍生物
JP5968881B2 (ja) * 2010-06-30 2016-08-10 レオ ファーマ アクティーゼルスカブ カルシウム模倣化合物の新規多形
WO2015082583A1 (en) * 2013-12-05 2015-06-11 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
UA116182C2 (uk) 2014-07-18 2018-02-12 Ґрін Кросс Корпорейшн Кристалічна форма метансульфонату 5-хлор-n-({(5s)-2-оксо-3-[4-(5,6-дигідро-4h-[1,2,4]триазин-1-іл)феніл]-1,3-оксазолідин-5-іл}метил)тіофен-2-карбоксаміду та фармацевтична композиція, що його містить
EP3144393A1 (en) * 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
CN107417626B (zh) * 2016-05-23 2020-01-24 江苏奥赛康药业有限公司 一种2-氨基嘧啶类化合物的多晶型形式
CN107474057B (zh) * 2016-06-07 2021-03-12 天津药物研究院有限公司 (5-(2-腈基苄基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶-2-基)乙酸酯盐酸盐的晶型及其制备方法和用途
US10570147B2 (en) * 2017-06-13 2020-02-25 Biotheryx, Inc. Bicyclic compounds and methods of use
JP7074782B2 (ja) * 2017-06-30 2022-05-24 トロフィー エスアーエス 患者位置決めアクセサリ検出を伴う口腔外歯科用撮像装置
EP3800190A4 (en) * 2018-05-02 2022-01-26 Tianjin Hemay Pharmaceutical Co., Ltd. SOLID FORM OF THIOPHENE DERIVATIVE

Also Published As

Publication number Publication date
BR112020021945A2 (pt) 2021-01-26
CA3098931C (en) 2023-10-24
AU2019262284A1 (en) 2020-12-24
JP2021522348A (ja) 2021-08-30
WO2019210867A1 (zh) 2019-11-07
CN116813637A (zh) 2023-09-29
CA3099072A1 (en) 2019-11-07
AU2019262282B2 (en) 2022-04-28
JP2021523891A (ja) 2021-09-09
CN116947878A (zh) 2023-10-27
CN110437251B (zh) 2023-07-21
AU2019262282A1 (en) 2020-11-12
US20210139498A1 (en) 2021-05-13
US11274104B2 (en) 2022-03-15
KR20210022557A (ko) 2021-03-03
PT3789389T (pt) 2025-12-17
CN110437249B (zh) 2023-07-21
DK3789389T3 (da) 2025-11-10
BR112020021976A2 (pt) 2021-01-26
CA3098927A1 (en) 2019-11-07
EP4335515A2 (en) 2024-03-13
ES3047059T3 (en) 2025-12-03
KR20210025001A (ko) 2021-03-08
WO2019210865A1 (zh) 2019-11-07
EP3789389B1 (en) 2025-10-08
EP4335515A3 (en) 2024-07-03
US12227514B2 (en) 2025-02-18
EP3789387B1 (en) 2024-02-28
EP3789389A1 (en) 2021-03-10
EP3789388B1 (en) 2024-01-24
CA3098931A1 (en) 2019-11-07
US20210238191A1 (en) 2021-08-05
AU2019262286A1 (en) 2020-11-12
CN110437251A (zh) 2019-11-12
EP3789389A4 (en) 2022-01-26
EP3800190A1 (en) 2021-04-07
CA3099071A1 (en) 2019-11-07
KR102701245B1 (ko) 2024-08-30
WO2019210864A1 (zh) 2019-11-07
BR112020022186A2 (pt) 2021-02-02
KR20210025000A (ko) 2021-03-08
CA3098927C (en) 2023-10-03
AU2019263865B2 (en) 2022-01-27
CA3213055A1 (en) 2019-11-07
JP7481263B2 (ja) 2024-05-10
JP7542523B2 (ja) 2024-08-30
PL3789389T3 (pl) 2026-03-16
CN110437250A (zh) 2019-11-12
CN110437249A (zh) 2019-11-12
US12180222B2 (en) 2024-12-31
JP2021523890A (ja) 2021-09-09
EP3789388A4 (en) 2021-06-09
KR20210022556A (ko) 2021-03-03
KR102839924B1 (ko) 2025-07-29
AU2019262286B2 (en) 2022-08-11
US11396518B2 (en) 2022-07-26
CN116836178A (zh) 2023-10-03
CN116854705A (zh) 2023-10-10
EP3800190A4 (en) 2022-01-26
JP2021523935A (ja) 2021-09-09
EP3789388A1 (en) 2021-03-10
KR102686835B1 (ko) 2024-07-22
CN110437250B (zh) 2023-06-23
EP3789387A1 (en) 2021-03-10
JP2024026251A (ja) 2024-02-28
US20210230181A1 (en) 2021-07-29
EP3789387A4 (en) 2021-06-30
WO2019210869A1 (zh) 2019-11-07
JP7477459B2 (ja) 2024-05-01
AU2019263865A1 (en) 2020-12-24
US20210380600A1 (en) 2021-12-09
BR112020022190A2 (pt) 2021-02-02

Similar Documents

Publication Publication Date Title
CA2938280C (en) 4-amino-imidazoquinoline compounds
JP2025176008A5 (enExample)
US8889699B2 (en) 5-fluorouracil derivative
CN110590749B (zh) 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用
CN103539795A (zh) 阿哌沙班的多晶型及其制备方法
US20140371273A1 (en) Polymorphs of perampanel
WO2012063933A1 (ja) ６，７－不飽和－７－カルバモイルモルヒナン誘導体の結晶およびその製造方法
CN104039796A (zh) 1-氧代/酰化-14-酰化的冬凌草甲素衍生物、及其制备方法和应用
AU2021341258A1 (en) CD73 inhibitor and application thereof in medicine
FI3789389T3 (fi) (S)-N-[5-[l-(3-etoksi-4-metoksifenyyli)-2-(metyylisulfonyyli)etyyli]-4,6-diokso-5,6-dihydro-4H-tieno[3,4-c]pyrrol-1-yyli]asetamidin kidemuoto
JP2022511800A5 (enExample)
WO2011033307A1 (en) Nilotinib dihydrochloride salt
JP6298768B2 (ja) ７−置換ハンファンギチンｂ誘導体、その調製方法及び使用
JP2019510801A5 (enExample)
JP2013520488A5 (enExample)
JP2021522348A5 (enExample)
US9713615B2 (en) Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds
WO2013065063A1 (en) Anhydrous form of dasatinib, process for its preparation and its use
JP2017206439A (ja) ホモジナイザーを用いる抗腫瘍剤の製造方法
DK2862869T3 (en) ACYLATED DERIVATIVES OF POLYPHYLLINE I, METHOD OF PREPARING IT AND USING THEREOF
JP2020530497A (ja) ３−（５−フルオロベンゾフラン−３−イル）−４−（５−メチル−５Ｈ−［１，３］ジオキソロ［４，５−ｆ］インドール−７−イル）ピロール−２，５−ジオンの固体形態
JP2020524707A (ja) 塩酸メフパリブの多形体およびその製造方法と使用
JP6059734B2 (ja) ２−アルキル−又は２−アリール−置換タンシノン誘導体、その調製方法及び適用
CN120817935A (zh) 一种杂(芳)环取代环状二胺类化合物及其在制备治疗和/或预防肿瘤药物中的应用
JP2006528947A5 (enExample)